Optimizing the ‘When’ of Exercise: Afternoon and Evening Activity as a Precision Medicine Tool for Diabetes Risk Reduction
Posted inDiabetes & Endocrinology Internal Medicine news

Optimizing the ‘When’ of Exercise: Afternoon and Evening Activity as a Precision Medicine Tool for Diabetes Risk Reduction

New evidence from the UK Biobank and NHANES suggests that the timing of moderate-to-vigorous physical activity (MVPA) significantly impacts type 2 diabetes risk. Clustering activity in the afternoon and evening provides superior metabolic protection compared to morning sessions, independent of the total volume of exercise performed.
OGTT-Derived Surrogate Indexes Outperform Fasting Measures in Predicting Type 2 Diabetes Risk: A Longitudinal Analysis
Posted inDiabetes & Endocrinology Internal Medicine news

OGTT-Derived Surrogate Indexes Outperform Fasting Measures in Predicting Type 2 Diabetes Risk: A Longitudinal Analysis

A longitudinal study of 2,260 participants confirms that oral glucose tolerance test (OGTT)-based surrogate indexes, particularly Gutt and Cederholm, are superior to fasting-only measures in predicting type 2 diabetes, providing high clinical utility for metabolic risk stratification.
Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial
Posted inDiabetes & Endocrinology Neurology news

Long-Term Benfotiamine Treatment Fails to Improve Diabetic Polyneuropathy: Insights from the BOND Randomized Controlled Trial

The 12-month BOND study found that high-dose benfotiamine (600 mg daily) did not significantly improve corneal nerve fiber length or other neurophysiological markers in patients with type 2 diabetes and symptomatic polyneuropathy, despite successfully increasing systemic thiamine levels.
Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control
Posted inDiabetes & Endocrinology Internal Medicine news

Uncoupling GIP from GLP-1: Long-Acting GIPR Agonist LY3537021 Demonstrates Independent Efficacy in Weight Loss and Glycemic Control

This Phase 1 study reveals that LY3537021, a long-acting GIPR agonist, independently drives significant weight loss and improves glucose regulation with a favorable safety profile and a 12-day half-life, clarifying the distinct therapeutic role of GIP in metabolic disease management.